Mytolac (Lanreotide Acetate)

Lanreotide acetate mimics the natural hormone somatostatin and binds to somatostatin receptors on endocrine cells. This binding blocks the release of several hormones, including growth hormone and various gastrointestinal peptides, thereby reducing disease‑related hormone excess.

The dose of Mytolac is individualized by the prescribing physician based on the patient’s condition, disease severity, and response to therapy. The prescriber determines the appropriate amount, frequency, and duration of treatment.

Safety of Mytolac in pregnancy or while breastfeeding has not been fully established. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when possible.

To request Mytolac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Mytolac (lanreotide acetate) and other somatostatin analogues such as octreotide share a similar mechanism of receptor binding and hormone suppression. Differences may include dosing frequency, formulation (long‑acting depot versus short‑acting), and specific approved indications, which clinicians consider when selecting therapy.

Mytolac should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and keep the product in its original packaging.

Mytolac is given by subcutaneous injection, typically using a pre‑filled syringe or autoinjector. The injection site is rotated among the abdomen, thigh or upper arm to minimise local irritation.

Serious adverse events include gallstone formation, severe hyperglycaemia or new‑onset diabetes, pancreatitis, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of these conditions and managed promptly if they occur.

Mytolac is contraindicated in patients with known hypersensitivity to lanreotide acetate or any component of the formulation. Caution is advised for individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease.